Axon Enterprise’s surreal growth makes it replace Moderna at Nasdaq Composite
Moderna, the company Axon replaced, had been performing quite well over the last couple of years, due to the demand of massive medications across the world due to the Covid-19 pandemic, as well as the need for vaccinations. However, its growth rate had come to a slight halt towards the end of 2024, and now Axon Enterprise will be taking its place, which is boasting of gain percentages of 110,600% since its IPO kicked off in the mid-2001s.
Why is Axon Enterprise so popular among US investors?
Although this kind of growth seems scary at the US stock market, US investors are still flocking in to take holding of this stock before the prices of it surge even higher as per reports. Axon is focused around law enforcement-related equipment, with their biggest boast being flagship Taser stun gun. The company’s mission from the start has been to decrease suspect injuries, increase the safety of law enforcement officers across the country, and improve community relations between the public and the police, which are the core reasons why Axon is so popular in the US.
Disclaimer Statement: This content is authored by a 3rd party. The views expressed here are that of the respective authors/ entities and do not represent the views of Economic Times (ET). ET does not guarantee, vouch for or endorse any of its contents nor is responsible for them in any manner whatsoever. Please take all steps necessary to ascertain that any information and content provided is correct, updated, and verified. ET hereby disclaims any and all warranties, express or implied, relating to the report and any content therein.
